POST Online Media Lite Edition


Eli Lilly partners with Area Health Systems on important antibody infusion therapies for COVID-19

Christian Fernsby |
Eli Lilly and Company has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important COVID-19 treatments.

Article continues below


Multiple neutralizing antibody therapies, administered via intravenous infusion, have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients.

The opening of these infusion centers provides additional dedicated locations in which people can receive COVID-19 infusion treatments.

Last week Ascension St. Vincent Evansville opened a dedicated infusion center to serve Hoosiers in southern Indiana who are high-risk COVID-19 patients.

Lilly has also partnered with the State of Indiana, Community Health Network, Eskenazi Health, and Franciscan Health on an infusion center serving the Central Indiana area and with Saint Joseph Health System, Beacon Health System, and Goshen Health System on an infusion center serving Northern Indiana.

These infusion centers have helped deliver antibody therapy to more than 1,700 Hoosiers with COVID-19 who are high risk.

What to read next

Eli Lilly says antibody drug cuts coronavirus hospitalization
Eli Lilly starts phase 3 trial of antibody treatments against coronavirus in care facilities
CVS Caremark to buy Coram from Apria Healthcare